Alys Pharmaceuticals is positioned as an innovative leader in the field of immuno-dermatology, focusing on redefining treatment paradigms for various dermatological conditions. The company has developed a robust research and development (R&D) pipeline that is supported by multiple platform technologies. This pipeline includes over a dozen active programs targeting significant dermatological indications such as atopic dermatitis, vitiligo, and alopecia areata, as well as underserved conditions like mastocytosis and cutaneous T-cell lymphoma. Alys aims to leverage cutting-edge scientific advancements to deliver transformative solutions to patients worldwide, with a vision to address major unmet medical needs in dermatology.

The formation of Alys Pharmaceuticals is a result of the merger of six asset-centric companies, which allows for a diverse and rich pipeline of innovative therapeutic modalities. The leadership team comprises renowned experts in dermatology and related scientific fields, including Nobel Prize winner Craig Mello and other prominent figures from prestigious institutions. Alys is committed to collaborative research, working with leading academic and research institutions to advance its programs. The company anticipates significant growth in its pipeline over the next few years, with plans to achieve multiple clinical Proof-of-Concept readouts and advance at least one program to registrational studies, thereby enhancing its impact on the treatment landscape in immuno-dermatology.

United States

Launched in February 2024, Alys Pharmaceuticals is an innovation leader in immuno-dermatology, co-founded by Medixci and world-leading dermatology and scientific experts. Originating from the aggregation of six asset-centric Medixci compannies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications. With a vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet medical need, Alys aspires to redefine the landscape of dermatological treatments.

Alys Pharmaceuticals

Company Details